<DOC>
	<DOCNO>NCT01904942</DOCNO>
	<brief_summary>The project base case-control study include cirrhotic patient ( 200 case ) without ( 400 control ) Hepatocellular carcinoma . The determination sample size proteomic spectroscopic study adapt high dimensional setting . The proteomic analysis conduct Clinical Innovation Proteomic Platform Dijon . Two approach use proteomic study : A global approach base comparison proteomic spectrum profile obtain mass spectrometry analysis ( MALDI-TOF ) . The particularity study regard previous study : procedure use purify sub proteome ( Five automate method include depletion fractionation purification apply ) , qualification generate data introduction quality control , high number sample include study . The second approach BIA-MS ( Biomolecular interaction analysis mass spectrometry ) target approach allow capture , quantification characterization protein . The quality control allow quantify various variability source validate biological variability higher technical variability . All sample treat analyzed protocol , 100 sample use validate marker statistical model develop analysis first 500 sample . The infra-red spectroscopy analysis conduct MÃ©DIAN team , CNRS UMR 6237 Reims university . The first 300 sample feature selection reference spectrum , classify different class mean mathematical classification method multivariate statistical process pattern recognition , neuronal network , support vector machine method case-based classification machine learning , genetic algorithm method evolutionary programming . The analysis second set sample ( 300 ) validate different mathematical classification method develop . In global study investigator unravel relationship proteomic , spectroscopic metabolic/nutritional data . The description relationship use canonical analysis multi-block analysis general extent . The goal method explore relationship may exist several group quantitative variable observe set individual .</brief_summary>
	<brief_title>Study Hepatocellular Carcinoma Cirrhotic Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Cases control male age 35 old , give inform consent participate study . All HCC case evolve cirrhotic liver , whatever etiology cirrhosis , include . Criteria diagnosis HCC define European Association Study Liver ( EASL ) ( Bruix J , J Hepatol 2001 ) : All patient cirrhosis , whatever etiology , include . The diagnosis cirrhosis rely histological confirmation liver biopsy : In patient free portal thrombosis Doppler imaging , presence portal hypertension ascertain biological ( tricytopenia ) , morphologic ( abdominal US , CT MRI ) , hepatic venous pressure measurement upper endoscopy ( mosaic gastropathy , varix ) . In patient portal thrombosis , presence portal hypertension associate : Clinical ( hepatomegaly clinical evidence hepatocellular failure : spider naevi , palmar erythema , white nail , gynecomastia ) morphological sign cirrhosis ( enlarge liver , nodular surface , sharp low edge ) . And/or biological sign hepatocellular failure ( TP &lt; 70 % , low albuminemia ) And/or sinusoidal block assess liver venous gradient &gt; 18 mm Hg In present state knowledge , fibrotest value 4 fibroscan value &gt; 12,5 kPa Without clinical biological sign consider diagnosis criterion cirrhosis chronic viral C hepatitis . The lack HCC cirrhotic patient inclusion assess good quality image examination ( abdominal US , CT scan MRI ) AFP 100 ng/ml . patient 35years old 75 year age cancer evolution HIV infection major somatic psychiatric illness compatible inclusion study non HCC primary liver cancer .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>